Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

H. pylori treatment regimens should achieve 70% minimum cure rate -- FDA draft guidance.

Executive Summary

H. PYLORI REGIMENS SHOULD ACHIEVE MINIMUM CURE RATE OF 70%, FDA recommends in its draft guidance to industry on "Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products." The draft states that "the minimum number of patients recommended in a [Helicobacter pylori] study would be 178 if the mean cure rate is 70% and the lower 95% confidence limit is 60%." An advisory committee meeting to discuss the draft guidance has been scheduled for March 5-7 ("The Pink Sheet" Feb. 17, In Brief).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel